Stock AnalizVaxcyte, Inc. PCVX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Vaxcyte, Inc. (PCVX) is a healthcare company listed in the US with a market value of about $10.0B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -23%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$767M | -$464M | -$402M | -$223M | -$100M | -$89M | -$50M | -$29M |
| Free cash flow | -$669M | -$475M | -$313M | -$176M | -$128M | -$48M | -$48M | -$32M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 | $-13.25 | $-8.12 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -26.0% | -13.3% | -29.1% | -18.9% | -27.2% | -20.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $116.40, 84% above the current price; targets range from $75.00 to $163.00; the consensus rating is “Strong buy”; expected EPS is $-7.86 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Vaxcyte pay a dividend?
Not currently.
Is Vaxcyte a good stock to buy?
We do not give buy or sell advice. Vaxcyte scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.